The findings were detailed in JAMA Otolaryngology–Head & Neck Surgery, as reported by Asharq Al-Awsat.
Combination Nasal Spray Relieves Stubborn Blockage Without Rebound Congestion
- What was tested: A new prescription nasal spray combining a fast-acting blood vessel shrinker (oxymetazoline) with an anti-inflammatory steroid (budesonide).
- The key result: 83 percent of participants with stubborn nasal blockage felt significantly better after four weeks, compared to just 36 percent who took the steroid alone.
- The safety profile: Crucially, patients did not experience rhinitis medicamentosa, commonly known as rebound congestion, which usually stops doctors from prescribing oxymetazoline for more than a few days.
Trial Design and Efficacy of the Combination Spray
Chronic nasal obstruction involves persistent difficulty moving air through the nasal passages due to swollen mucosal tissue, excess mucus production, or anatomical barriers. Conditions such as chronic sinusitis, severe allergies, or a deviated septum frequently drive this pathology, disrupting respiration, sleep architecture, and olfactory function.
To evaluate whether a dual-action approach could safely bypass these clinical hurdles, investigators enrolled 60 adult patients who had failed to find relief with traditional monotherapy steroid sprays. The clinical team divided the cohort into two distinct treatment arms. Both treatments were administered twice daily for four weeks, followed by a three-week tapering protocol.
By week four, 83 percent of patients using the combination treatment achieved at least a moderate clinical improvement on standardized assessment metrics. In stark contrast, only 36 percent of participants in the steroid-only arm reached that same clinical benchmark. The combination therapy reduced patient-reported congestion severity scores by a wide margin at the two-week mark, whereas the single-agent group saw a smaller reduction.
| Treatment Arm | Moderate Improvement Rate (Week 4) | Congestion Severity Reduction (Week 2) |
|---|---|---|
| Oxymetazoline + Budesonide Spray | 83% | Significant reduction |
| Budesonide Monotherapy | 36% | Notable reduction |
Addressing the Rebound Congestion Paradox
The primary pharmacological barrier in treating chronic nasal obstruction is the prevention of rhinitis medicamentosa. Oxymetazoline operates via a specific mechanism of action: it acts as an alpha-adrenergic receptor agonist, stimulating blood vessels in the nasal mucosa to constrict rapidly. This constriction shrinks swollen tissue and widens airway passages.
However, prolonged independent use of this decongestant routinely leads to tachyphylaxis—a rapid decrease in drug responsiveness—followed by severe rebound swelling when the medication wears off. Patients then enter a cyclical trap of increased dosing, escalating mucosal inflammation, and chronic dependency.
During the four-week trial period, researchers documented zero clinical signs of rebound congestion or aggravated swelling among patients using the combination formulation, despite maintaining full therapeutic doses of the decongestant. Participants completed the tapering phase during weeks five and six without experiencing acute symptom deterioration. Following a complete seven-day cessation of oxymetazoline, 75 percent of patients whose symptoms were controlled maintained their clinical gains without requiring a return to the medication.
Regulators Require Larger Clinical Trials Before Approving the Spray
Because the investigation evaluated a modest cohort of 60 participants over a seven-week timeline, regulatory bodies such as the U.S. Food and Drug Administration (FDA) will require larger, multi-center, double-blind placebo-controlled trials before considering widespread clinical approval.
References
- JAMA Otolaryngology–Head & Neck Surgery. “Efficacy of a Novel Intranasal Combination Spray for Chronic Nasal Obstruction.” American Medical Association.
- Asharq Al-Awsat. “انسداد الأنف المزمن… بخّاخ يُحقّق تحسّناً لدى 83 % من المرضى.”
- Al-Khabbar News.
